| Literature DB >> 26661119 |
Christine Paul1,2, Luke Wolfenden1,2,3, Flora Tzelepis1,2,3, Serene Yoong1,2,3, Jenny Bowman1,2, Paula Wye2,3, Emma Sherwood1,2, Shiho Rose1,2, John Wiggers1,2,3.
Abstract
In Australia and New Zealand, population groups who experience social disadvantage smoke at much higher rates than the general population. As there are limited data specific to these groups regarding the success of nicotine replacement therapy for smoking cessation, this commentary will provide an overview of the relevant international literature supplemented with observational data relevant to the policy contexts in Australia and New Zealand. [Paul C, Wolfenden L, Tzelepis F, Yoong S, Bowman J, Wye P, Sherwood E, Rose S, Wiggers J. Nicotine replacement therapy as a smoking cessation aid among disadvantaged smokers: What answers do we need? Drug Alcohol Rev 2016;35:785-789].Entities:
Keywords: Australia; New Zealand; nicotinic agonist; population group; smoking cessation
Mesh：
Substances：
Year: 2015 PMID： 26661119 DOI： 10.1111/dar.12362
Source DB: PubMed Journal: Drug Alcohol Rev ISSN： 0959-5236